Ammar Alqaid, MD
Internal Medicine · Shreveport, LANPI 1235484692
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (54.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 67.6% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2022 at $7,676 and has fallen 76.2% since, to $1,827 in 2025. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $106.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$12K
- Boehringer Ingelheim$1K
- Medtronic$963
- Body Vision Medical Inc.$860
- Actelion Pharmaceuticals US, Inc.$473
- Galvanize Therapeutics, Inc$312
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$5003%
- Travel & lodging$2,72315%
- Food & beverage$4,95028%
- Education$9,62554%
- Gifts$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 34 | $12,041 |
| Boehringer Ingelheim | 21 | $1,138 |
| Medtronic | 10 | $963 |
| Body Vision Medical Inc. | 6 | $860 |
| Actelion Pharmaceuticals US, Inc. | 27 | $473 |
| Galvanize Therapeutics, Inc | 3 | $312 |
| AstraZeneca(2 entities) | 6 | $306 |
| GSK | 8 | $231 |
| Johnson & Johnson | 14 | $204 |
| Veran Medical Technologies, Inc. | 3 | $175 |
| Mallinckrodt Hospital Products Inc. | 1 | $145 |
| Grifols USA, LLC | 2 | $123 |
| Insmed, Inc. | 1 | $115 |
| Pulmonx Corporation | 2 | $115 |
| Merck | 7 | $90 |
| Inari Medical, Inc. | 1 | $84 |
| E.r. Squibb & Sons, L.L.C. | 6 | $76 |
| Pfizer | 4 | $73 |
| Regeneron Healthcare Solutions, Inc. | 2 | $71 |
| Baxter Healthcare | 1 | $43 |
| Gilead | 2 | $31 |
| Verona Pharma, Inc. | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Sandoz | 1 | $22 |
| Shionogi Inc | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$6,000
- Da Vinci Surgical System$5,393
- ILLUMISITE$789
- LungVision$735
- OFEV$466
- ALIYA SYSTEM$281
- TEZSPIRE$246
- Spin$162
- TERLIVAZ$145
- OPSUMIT$124
- NUCALA$121
- Arikayce$115
How this compares
$17,811 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $35,451 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $12,930 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $9,941 |
| Spiriva HandihalerTiotropium Bromide | 13 | $7,454 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $6,892 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $5,001 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $687 |
| Prednisone | 27 | $86 |
| Furosemide | 15 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $231 | $58,32280 claims |
| Boehringer IngelheimStiolto Respimat | $1,138 | $6,89214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Shreveport
- Rajan KhannaShreveport$54K
- Wendell WallShreveport$25K
- Bharat SachdevaShreveport$24K
- Attila BaloghShreveport$18K
- Paul RushingShreveport$13K
- Allan Matriano-LimShreveport$12K
- Scott McRightShreveport$12K
- Furqan AkhtarShreveport$11K
- Roan FlennikenShreveport$11K
- Donna RyanBaton Rouge$991K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.